Australia markets close in 5 hours 12 minutes

Aimmune Therapeutics, Inc. (AIMT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.99-0.37 (-2.58%)
At close: 4:00PM EDT

13.99 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Loading interactive chart…
  • Could This Small-Cap Biotech Stock Make You Rich?
    Motley Fool

    Could This Small-Cap Biotech Stock Make You Rich?

    Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.

  • Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
    Business Wire

    Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

    Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  • Aimmune Therapeutics (AIMT) Q2 2020 Earnings Call Transcript
    Motley Fool

    Aimmune Therapeutics (AIMT) Q2 2020 Earnings Call Transcript

    Before we begin, I would like to remind you that during today's call and Q&A session, we will be making forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of these forward-looking statements include the effects of the COVID-19 pandemic on our business and financial condition; the expectation that Aimmune will need additional funds to finance its operations; Aimmune's dependence on the success of PALFORZIA; Aimmune's ability to build a commercial field organization and distribution network; the degree of acceptance of PALFORZIA among physicians, patients, healthcare payers, patient advocacy groups and the general medical community; Aimmune's ability to obtain favorable coverage and reimbursement from third-party payers for PALFORZIA; Aimmune's ability to implement and comply with the REMS for PALFORZIA; Aimmune's or any of its collaborative partners' ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune's or any of its collaborative partners' clinical trials will not be successful; the reliance on third parties for the manufacture of PALFORZIA and our product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune's ability to attract and retain senior management personnel.